Compare Danaher Corporation (DHR) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nucor Corporation — how do they compare? Danaher Corporation trades at $200.46 (market cap $140.88B), while Nucor Corporation trades at $235 (market cap $53.33B). The key difference: Danaher Corporation is far larger — about 2.6× Nucor Corporation's market cap, and Nucor Corporation pays the higher dividend (0.96%). Which is the better fit depends on your goals.
| DHR | NUE | |
|---|---|---|
Market Cap | $140.88B | $53.33B |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $266.35 |
52-Week Low | $161.91 | $131.78 |
Enterprise Value | $153.66B | $57.97B |
Dividend Yield | 0.8% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Nucor (NUE) trades at $233.00, up 2.48% over the past day, supported by a bullish technical signal and strong earnings beats in recent quarters. The stock benefits from a solid balance sheet with a debt-to-asset ratio of 20.23% (2025 company filing) and a 53-year dividend growth streak. Revenue for 2025 was $32.49 billion, with net income of $1.74 billion, though margins have compressed from peak levels. Recent news highlights a joint venture to address power infrastructure bottlenecks and positive analyst sentiment.
Outlook remains positive with a consensus price target of $262.89 (analyst reports July 2026), implying ~13% upside. Key opportunities include steel price strength and strategic expansions, but risks involve cyclical demand weakness and margin pressure. Institutional ownership trends and buy ratings (62.5% of analysts) support a constructive view, though investors should monitor Q2 2026 earnings for confirmation of guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
